Global Acellular Pertussis-based Hexavalent Combination Vaccine Supply, Demand and Key Producers, 2026-2032
The global Acellular Pertussis-based Hexavalent Combination Vaccine market size is expected to reach $ 3518 million by 2032, rising at a market growth of 5.5% CAGR during the forecast period (2026-2032).
An acellular pertussis-based hexavalent combination vaccine is a multivalent pediatric vaccine designed primarily for the primary immunization and, depending on national recommendations and product authorization, booster immunization of infants and young children. It is commonly designated as DTaP-IPV-HepB-Hib and combines diphtheria toxoid, tetanus toxoid, purified acellular pertussis antigens, inactivated poliovirus antigens, recombinant hepatitis B surface antigen, and a conjugated Haemophilus influenzae type b antigen. It therefore provides protection against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases caused by Hib. Compared with schedules using several monovalent or lower-valency vaccines, a hexavalent vaccine can reduce the number of injections, clinic visits and administration procedures, improving the convenience and operational efficiency of pediatric immunization. It is a technologically complex biological product rather than a simple antigen mixture, requiring multiple fermentation, cell-culture, recombinant-expression, purification, detoxification, conjugation, adsorption and formulation platforms, together with rigorous control of antigen compatibility, potency and manufacturing consistency.In 2025, global Acellular Pertussis-based Hexavalent Combination Vaccine production reached approximately 29 million units.The average gross profit margin of this product is 85%.
The principal market opportunity is the continuing transition of pediatric immunization programs from fragmented, injection-intensive schedules toward simplified combination-vaccine schedules. Hexavalent products can preserve broad disease protection while reducing injections, appointment requirements and vaccine-handling procedures, potentially lowering the risk of delayed, missed or incomplete vaccination. The renewed circulation of pertussis in a number of regions has also reinforced the importance of timely completion of infant pertussis immunization. In established markets, demand is supported by the continued optimization of national childhood vaccination schedules and replacement of older combination products. In emerging economies, a larger long-term opportunity may arise as immunization systems move from pentavalent vaccines combined with separately administered hepatitis B or inactivated polio vaccines toward integrated hexavalent formulations. These trends favor companies with established antigen platforms, internationally compliant manufacturing capacity, dependable supply and experience in multinational registration and public-sector procurement.
The principal barriers arise from scientific, manufacturing and regulatory complexity rather than an absence of medical need. Six antigen components must deliver appropriate immune responses and acceptable safety profiles within a common formulation or vaccination system, while avoiding clinically meaningful interference between components. Variability in one antigen, an interruption in a critical raw material or a delay in batch release can affect the availability of the entire vaccine. Manufacturers must also conduct extensive clinical evaluations covering primary schedules, booster use, interchangeability and co-administration with other pediatric vaccines, followed by continuous pharmacovigilance. Commercialization is further complicated by differences in national immunization schedules, tendering systems, reimbursement policies, local supply requirements and price negotiations. Waning pertussis immunity, changes in birth cohorts, vaccine hesitancy and fluctuations in government immunization budgets may also influence demand. Established products benefit from extensive clinical experience and physician confidence, creating a substantial time and credibility barrier for new entrants.
Downstream purchasing criteria are expanding beyond disease coverage to include schedule efficiency, completion rates, supply reliability and value across the entire vaccination pathway. National immunization programs and public procurement agencies increasingly evaluate whether a vaccine can simplify delivery, reduce operational complexity at primary-care facilities and maintain dependable long-term supply. Private hospitals, pediatric clinics and self-pay vaccination markets place greater emphasis on fewer injections, convenient presentations, established safety records and parental acceptance. Digital immunization registries, appointment reminders and integrated child-health management systems are also improving the visibility of missed doses and supporting more standardized vaccination pathways, which strengthens the clinical value of combination vaccines. Future market expansion is therefore expected to be driven primarily by structural substitution for fragmented vaccination schedules rather than birth-cohort growth alone. Products capable of supporting both primary and booster strategies, adapting to different national schedules and demonstrating consistent real-world safety performance will be better positioned in downstream markets.
This report studies the global Acellular Pertussis-based Hexavalent Combination Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Acellular Pertussis-based Hexavalent Combination Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Acellular Pertussis-based Hexavalent Combination Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Acellular Pertussis-based Hexavalent Combination Vaccine total production and demand, 2021-2032, (K Dose)
Global Acellular Pertussis-based Hexavalent Combination Vaccine total production value, 2021-2032, (USD Million)
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Acellular Pertussis-based Hexavalent Combination Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Acellular Pertussis-based Hexavalent Combination Vaccine domestic production, consumption, key domestic manufacturers and share
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Acellular Pertussis-based Hexavalent Combination Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Sanofi, MSP Vaccine Company, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Acellular Pertussis-based Hexavalent Combination Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Acellular Pertussis-based Hexavalent Combination Vaccine Market, By Region:
1. How big is the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
2. What is the demand of the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
3. What is the year over year growth of the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
4. What is the production and production value of the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
5. Who are the key producers in the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
6. What are the growth factors driving the market demand?
An acellular pertussis-based hexavalent combination vaccine is a multivalent pediatric vaccine designed primarily for the primary immunization and, depending on national recommendations and product authorization, booster immunization of infants and young children. It is commonly designated as DTaP-IPV-HepB-Hib and combines diphtheria toxoid, tetanus toxoid, purified acellular pertussis antigens, inactivated poliovirus antigens, recombinant hepatitis B surface antigen, and a conjugated Haemophilus influenzae type b antigen. It therefore provides protection against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases caused by Hib. Compared with schedules using several monovalent or lower-valency vaccines, a hexavalent vaccine can reduce the number of injections, clinic visits and administration procedures, improving the convenience and operational efficiency of pediatric immunization. It is a technologically complex biological product rather than a simple antigen mixture, requiring multiple fermentation, cell-culture, recombinant-expression, purification, detoxification, conjugation, adsorption and formulation platforms, together with rigorous control of antigen compatibility, potency and manufacturing consistency.In 2025, global Acellular Pertussis-based Hexavalent Combination Vaccine production reached approximately 29 million units.The average gross profit margin of this product is 85%.
The principal market opportunity is the continuing transition of pediatric immunization programs from fragmented, injection-intensive schedules toward simplified combination-vaccine schedules. Hexavalent products can preserve broad disease protection while reducing injections, appointment requirements and vaccine-handling procedures, potentially lowering the risk of delayed, missed or incomplete vaccination. The renewed circulation of pertussis in a number of regions has also reinforced the importance of timely completion of infant pertussis immunization. In established markets, demand is supported by the continued optimization of national childhood vaccination schedules and replacement of older combination products. In emerging economies, a larger long-term opportunity may arise as immunization systems move from pentavalent vaccines combined with separately administered hepatitis B or inactivated polio vaccines toward integrated hexavalent formulations. These trends favor companies with established antigen platforms, internationally compliant manufacturing capacity, dependable supply and experience in multinational registration and public-sector procurement.
The principal barriers arise from scientific, manufacturing and regulatory complexity rather than an absence of medical need. Six antigen components must deliver appropriate immune responses and acceptable safety profiles within a common formulation or vaccination system, while avoiding clinically meaningful interference between components. Variability in one antigen, an interruption in a critical raw material or a delay in batch release can affect the availability of the entire vaccine. Manufacturers must also conduct extensive clinical evaluations covering primary schedules, booster use, interchangeability and co-administration with other pediatric vaccines, followed by continuous pharmacovigilance. Commercialization is further complicated by differences in national immunization schedules, tendering systems, reimbursement policies, local supply requirements and price negotiations. Waning pertussis immunity, changes in birth cohorts, vaccine hesitancy and fluctuations in government immunization budgets may also influence demand. Established products benefit from extensive clinical experience and physician confidence, creating a substantial time and credibility barrier for new entrants.
Downstream purchasing criteria are expanding beyond disease coverage to include schedule efficiency, completion rates, supply reliability and value across the entire vaccination pathway. National immunization programs and public procurement agencies increasingly evaluate whether a vaccine can simplify delivery, reduce operational complexity at primary-care facilities and maintain dependable long-term supply. Private hospitals, pediatric clinics and self-pay vaccination markets place greater emphasis on fewer injections, convenient presentations, established safety records and parental acceptance. Digital immunization registries, appointment reminders and integrated child-health management systems are also improving the visibility of missed doses and supporting more standardized vaccination pathways, which strengthens the clinical value of combination vaccines. Future market expansion is therefore expected to be driven primarily by structural substitution for fragmented vaccination schedules rather than birth-cohort growth alone. Products capable of supporting both primary and booster strategies, adapting to different national schedules and demonstrating consistent real-world safety performance will be better positioned in downstream markets.
This report studies the global Acellular Pertussis-based Hexavalent Combination Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Acellular Pertussis-based Hexavalent Combination Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Acellular Pertussis-based Hexavalent Combination Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Acellular Pertussis-based Hexavalent Combination Vaccine total production and demand, 2021-2032, (K Dose)
Global Acellular Pertussis-based Hexavalent Combination Vaccine total production value, 2021-2032, (USD Million)
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Acellular Pertussis-based Hexavalent Combination Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Acellular Pertussis-based Hexavalent Combination Vaccine domestic production, consumption, key domestic manufacturers and share
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Acellular Pertussis-based Hexavalent Combination Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Acellular Pertussis-based Hexavalent Combination Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Sanofi, MSP Vaccine Company, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Acellular Pertussis-based Hexavalent Combination Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Acellular Pertussis-based Hexavalent Combination Vaccine Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Prefilled
- Vial
- Public
- Private
- GSK
- Sanofi
- MSP Vaccine Company
1. How big is the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
2. What is the demand of the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
3. What is the year over year growth of the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
4. What is the production and production value of the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
5. Who are the key producers in the global Acellular Pertussis-based Hexavalent Combination Vaccine market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Acellular Pertussis-based Hexavalent Combination Vaccine Introduction
1.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Supply & Forecast
1.2.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.2.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Pricing Trends (2021-2032)
1.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (Based on Production Site)
1.3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2021-2032)
1.3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (2021-2032)
1.3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Region (2021-2032)
1.3.4 North America Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.5 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.6 China Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.7 Japan Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.8 India Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Acellular Pertussis-based Hexavalent Combination Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Acellular Pertussis-based Hexavalent Combination Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Demand (2021-2032)
2.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption by Region
2.2.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption by Region (2021-2026)
2.2.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.4 China Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.5 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.6 Japan Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.7 South Korea Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.8 ASEAN Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.9 India Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Manufacturer (2021-2026)
3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Manufacturer (2021-2026)
3.4 Acellular Pertussis-based Hexavalent Combination Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Acellular Pertussis-based Hexavalent Combination Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Acellular Pertussis-based Hexavalent Combination Vaccine in 2025
3.6 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Overall Company Footprint Analysis
3.6.1 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Region Footprint
3.6.2 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Type Footprint
3.6.3 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Comparison
4.1.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Comparison
4.2.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Comparison
4.3.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026)
4.5 China Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers and Market Share
4.5.1 China Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026)
4.6 Rest of World Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Prefilled
5.2.2 Vial
5.3 Market Segment by Type
5.3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Type (2021-2032)
5.3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type (2021-2032)
5.3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Public
6.2.2 Private
6.3 Market Segment by Application
6.3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Application (2021-2032)
6.3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application (2021-2032)
6.3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2021-2032)
7 COMPANY PROFILES
7.1 GSK
7.1.1 GSK Details
7.1.2 GSK Major Business
7.1.3 GSK Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
7.1.4 GSK Acellular Pertussis-based Hexavalent Combination Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
7.1.5 GSK Recent Developments/Updates
7.1.6 GSK Competitive Strengths & Weaknesses
7.2 Sanofi
7.2.1 Sanofi Details
7.2.2 Sanofi Major Business
7.2.3 Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
7.2.4 Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
7.2.5 Sanofi Recent Developments/Updates
7.2.6 Sanofi Competitive Strengths & Weaknesses
7.3 MSP Vaccine Company
7.3.1 MSP Vaccine Company Details
7.3.2 MSP Vaccine Company Major Business
7.3.3 MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
7.3.4 MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
7.3.5 MSP Vaccine Company Recent Developments/Updates
7.3.6 MSP Vaccine Company Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Acellular Pertussis-based Hexavalent Combination Vaccine Industry Chain
8.2 Acellular Pertussis-based Hexavalent Combination Vaccine Upstream Analysis
8.2.1 Acellular Pertussis-based Hexavalent Combination Vaccine Core Raw Materials
8.2.2 Main Manufacturers of Acellular Pertussis-based Hexavalent Combination Vaccine Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Acellular Pertussis-based Hexavalent Combination Vaccine Production Mode
8.6 Acellular Pertussis-based Hexavalent Combination Vaccine Procurement Model
8.7 Acellular Pertussis-based Hexavalent Combination Vaccine Industry Sales Model and Sales Channels
8.7.1 Acellular Pertussis-based Hexavalent Combination Vaccine Sales Model
8.7.2 Acellular Pertussis-based Hexavalent Combination Vaccine Typical Distributors
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Acellular Pertussis-based Hexavalent Combination Vaccine Introduction
1.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Supply & Forecast
1.2.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.2.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Pricing Trends (2021-2032)
1.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (Based on Production Site)
1.3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2021-2032)
1.3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (2021-2032)
1.3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Region (2021-2032)
1.3.4 North America Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.5 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.6 China Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.7 Japan Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.3.8 India Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Acellular Pertussis-based Hexavalent Combination Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Acellular Pertussis-based Hexavalent Combination Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Demand (2021-2032)
2.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption by Region
2.2.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption by Region (2021-2026)
2.2.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.4 China Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.5 Europe Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.6 Japan Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.7 South Korea Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.8 ASEAN Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
2.9 India Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Manufacturer (2021-2026)
3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Manufacturer (2021-2026)
3.4 Acellular Pertussis-based Hexavalent Combination Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Acellular Pertussis-based Hexavalent Combination Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Acellular Pertussis-based Hexavalent Combination Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Acellular Pertussis-based Hexavalent Combination Vaccine in 2025
3.6 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Overall Company Footprint Analysis
3.6.1 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Region Footprint
3.6.2 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Type Footprint
3.6.3 Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Comparison
4.1.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Comparison
4.2.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Comparison
4.3.1 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026)
4.5 China Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers and Market Share
4.5.1 China Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026)
4.6 Rest of World Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Prefilled
5.2.2 Vial
5.3 Market Segment by Type
5.3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Type (2021-2032)
5.3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type (2021-2032)
5.3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Public
6.2.2 Private
6.3 Market Segment by Application
6.3.1 World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Application (2021-2032)
6.3.2 World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application (2021-2032)
6.3.3 World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2021-2032)
7 COMPANY PROFILES
7.1 GSK
7.1.1 GSK Details
7.1.2 GSK Major Business
7.1.3 GSK Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
7.1.4 GSK Acellular Pertussis-based Hexavalent Combination Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
7.1.5 GSK Recent Developments/Updates
7.1.6 GSK Competitive Strengths & Weaknesses
7.2 Sanofi
7.2.1 Sanofi Details
7.2.2 Sanofi Major Business
7.2.3 Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
7.2.4 Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
7.2.5 Sanofi Recent Developments/Updates
7.2.6 Sanofi Competitive Strengths & Weaknesses
7.3 MSP Vaccine Company
7.3.1 MSP Vaccine Company Details
7.3.2 MSP Vaccine Company Major Business
7.3.3 MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
7.3.4 MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
7.3.5 MSP Vaccine Company Recent Developments/Updates
7.3.6 MSP Vaccine Company Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Acellular Pertussis-based Hexavalent Combination Vaccine Industry Chain
8.2 Acellular Pertussis-based Hexavalent Combination Vaccine Upstream Analysis
8.2.1 Acellular Pertussis-based Hexavalent Combination Vaccine Core Raw Materials
8.2.2 Main Manufacturers of Acellular Pertussis-based Hexavalent Combination Vaccine Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Acellular Pertussis-based Hexavalent Combination Vaccine Production Mode
8.6 Acellular Pertussis-based Hexavalent Combination Vaccine Procurement Model
8.7 Acellular Pertussis-based Hexavalent Combination Vaccine Industry Sales Model and Sales Channels
8.7.1 Acellular Pertussis-based Hexavalent Combination Vaccine Sales Model
8.7.2 Acellular Pertussis-based Hexavalent Combination Vaccine Typical Distributors
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (2021-2026) & (K Dose)
Table 7. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (2027-2032) & (K Dose)
Table 8. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Region (2021-2026)
Table 9. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Region (2027-2032)
Table 10. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Acellular Pertussis-based Hexavalent Combination Vaccine Major Market Trends
Table 13. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Acellular Pertussis-based Hexavalent Combination Vaccine Producers in 2025
Table 18. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Acellular Pertussis-based Hexavalent Combination Vaccine Producers in 2025
Table 20. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Acellular Pertussis-based Hexavalent Combination Vaccine Company Evaluation Quadrant
Table 22. World Acellular Pertussis-based Hexavalent Combination Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Acellular Pertussis-based Hexavalent Combination Vaccine Production Site of Key Manufacturer
Table 24. Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Type Footprint
Table 25. Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Application Footprint
Table 26. Acellular Pertussis-based Hexavalent Combination Vaccine Competitive Factors
Table 27. Acellular Pertussis-based Hexavalent Combination Vaccine New Entrant and Capacity Expansion Plans
Table 28. Acellular Pertussis-based Hexavalent Combination Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Acellular Pertussis-based Hexavalent Combination Vaccine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share (2021-2026)
Table 37. China Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share (2021-2026)
Table 47. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Type (2021-2026) & (K Dose)
Table 49. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Type (2027-2032) & (K Dose)
Table 50. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 55. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Application (2021-2026) & (K Dose)
Table 56. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Application (2027-2032) & (K Dose)
Table 57. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 58. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 59. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 60. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 61. GSK Basic Information, Manufacturing Base and Competitors
Table 62. GSK Major Business
Table 63. GSK Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
Table 64. GSK Acellular Pertussis-based Hexavalent Combination Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. GSK Recent Developments/Updates
Table 66. GSK Competitive Strengths & Weaknesses
Table 67. Sanofi Basic Information, Manufacturing Base and Competitors
Table 68. Sanofi Major Business
Table 69. Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
Table 70. Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 71. Sanofi Recent Developments/Updates
Table 72. Sanofi Competitive Strengths & Weaknesses
Table 73. MSP Vaccine Company Basic Information, Manufacturing Base and Competitors
Table 74. MSP Vaccine Company Major Business
Table 75. MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
Table 76. MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 77. MSP Vaccine Company Recent Developments/Updates
Table 78. MSP Vaccine Company Competitive Strengths & Weaknesses
Table 79. Global Key Players of Acellular Pertussis-based Hexavalent Combination Vaccine Upstream (Raw Materials)
Table 80. Global Acellular Pertussis-based Hexavalent Combination Vaccine Typical Customers
Table 81. Acellular Pertussis-based Hexavalent Combination Vaccine Typical Distributors
Table 1. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (2021-2026) & (K Dose)
Table 7. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Region (2027-2032) & (K Dose)
Table 8. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Region (2021-2026)
Table 9. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Region (2027-2032)
Table 10. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Acellular Pertussis-based Hexavalent Combination Vaccine Major Market Trends
Table 13. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Acellular Pertussis-based Hexavalent Combination Vaccine Producers in 2025
Table 18. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Acellular Pertussis-based Hexavalent Combination Vaccine Producers in 2025
Table 20. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Acellular Pertussis-based Hexavalent Combination Vaccine Company Evaluation Quadrant
Table 22. World Acellular Pertussis-based Hexavalent Combination Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Acellular Pertussis-based Hexavalent Combination Vaccine Production Site of Key Manufacturer
Table 24. Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Type Footprint
Table 25. Acellular Pertussis-based Hexavalent Combination Vaccine Market: Company Product Application Footprint
Table 26. Acellular Pertussis-based Hexavalent Combination Vaccine Competitive Factors
Table 27. Acellular Pertussis-based Hexavalent Combination Vaccine New Entrant and Capacity Expansion Plans
Table 28. Acellular Pertussis-based Hexavalent Combination Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Acellular Pertussis-based Hexavalent Combination Vaccine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share (2021-2026)
Table 37. China Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Acellular Pertussis-based Hexavalent Combination Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share (2021-2026)
Table 47. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Type (2021-2026) & (K Dose)
Table 49. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Type (2027-2032) & (K Dose)
Table 50. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 55. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Application (2021-2026) & (K Dose)
Table 56. World Acellular Pertussis-based Hexavalent Combination Vaccine Production by Application (2027-2032) & (K Dose)
Table 57. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 58. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 59. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 60. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 61. GSK Basic Information, Manufacturing Base and Competitors
Table 62. GSK Major Business
Table 63. GSK Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
Table 64. GSK Acellular Pertussis-based Hexavalent Combination Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. GSK Recent Developments/Updates
Table 66. GSK Competitive Strengths & Weaknesses
Table 67. Sanofi Basic Information, Manufacturing Base and Competitors
Table 68. Sanofi Major Business
Table 69. Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
Table 70. Sanofi Acellular Pertussis-based Hexavalent Combination Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 71. Sanofi Recent Developments/Updates
Table 72. Sanofi Competitive Strengths & Weaknesses
Table 73. MSP Vaccine Company Basic Information, Manufacturing Base and Competitors
Table 74. MSP Vaccine Company Major Business
Table 75. MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Product and Services
Table 76. MSP Vaccine Company Acellular Pertussis-based Hexavalent Combination Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 77. MSP Vaccine Company Recent Developments/Updates
Table 78. MSP Vaccine Company Competitive Strengths & Weaknesses
Table 79. Global Key Players of Acellular Pertussis-based Hexavalent Combination Vaccine Upstream (Raw Materials)
Table 80. Global Acellular Pertussis-based Hexavalent Combination Vaccine Typical Customers
Table 81. Acellular Pertussis-based Hexavalent Combination Vaccine Typical Distributors
LIST OF FIGURES
Figure 1. Acellular Pertussis-based Hexavalent Combination Vaccine Picture
Figure 2. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 5. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 9. Europe Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 10. China Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 11. Japan Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 12. India Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 13. Acellular Pertussis-based Hexavalent Combination Vaccine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 16. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Market Share by Region (2021-2032)
Figure 17. United States Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 18. China Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 19. Europe Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 20. Japan Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 21. South Korea Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 22. ASEAN Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 23. India Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 24. Producer Shipments of Acellular Pertussis-based Hexavalent Combination Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Acellular Pertussis-based Hexavalent Combination Vaccine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Acellular Pertussis-based Hexavalent Combination Vaccine Markets in 2025
Figure 27. United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share 2025
Figure 31. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share 2025
Figure 33. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Type in 2025
Figure 35. Prefilled
Figure 36. Vial
Figure 37. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Type (2021-2032)
Figure 38. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Type (2021-2032)
Figure 39. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 41. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Application in 2025
Figure 42. Public
Figure 43. Private
Figure 44. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Application (2021-2032)
Figure 45. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Application (2021-2032)
Figure 46. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 47. Acellular Pertussis-based Hexavalent Combination Vaccine Industry Chain
Figure 48. Acellular Pertussis-based Hexavalent Combination Vaccine Procurement Model
Figure 49. Acellular Pertussis-based Hexavalent Combination Vaccine Sales Model
Figure 50. Acellular Pertussis-based Hexavalent Combination Vaccine Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Figure 1. Acellular Pertussis-based Hexavalent Combination Vaccine Picture
Figure 2. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 5. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 9. Europe Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 10. China Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 11. Japan Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 12. India Acellular Pertussis-based Hexavalent Combination Vaccine Production (2021-2032) & (K Dose)
Figure 13. Acellular Pertussis-based Hexavalent Combination Vaccine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 16. World Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Market Share by Region (2021-2032)
Figure 17. United States Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 18. China Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 19. Europe Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 20. Japan Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 21. South Korea Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 22. ASEAN Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 23. India Acellular Pertussis-based Hexavalent Combination Vaccine Consumption (2021-2032) & (K Dose)
Figure 24. Producer Shipments of Acellular Pertussis-based Hexavalent Combination Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Acellular Pertussis-based Hexavalent Combination Vaccine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Acellular Pertussis-based Hexavalent Combination Vaccine Markets in 2025
Figure 27. United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Acellular Pertussis-based Hexavalent Combination Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share 2025
Figure 31. China Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share 2025
Figure 33. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Type in 2025
Figure 35. Prefilled
Figure 36. Vial
Figure 37. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Type (2021-2032)
Figure 38. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Type (2021-2032)
Figure 39. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 41. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Application in 2025
Figure 42. Public
Figure 43. Private
Figure 44. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Market Share by Application (2021-2032)
Figure 45. World Acellular Pertussis-based Hexavalent Combination Vaccine Production Value Market Share by Application (2021-2032)
Figure 46. World Acellular Pertussis-based Hexavalent Combination Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 47. Acellular Pertussis-based Hexavalent Combination Vaccine Industry Chain
Figure 48. Acellular Pertussis-based Hexavalent Combination Vaccine Procurement Model
Figure 49. Acellular Pertussis-based Hexavalent Combination Vaccine Sales Model
Figure 50. Acellular Pertussis-based Hexavalent Combination Vaccine Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
